Vaxcyte, Inc. (PCVX) Key Metrics
PCVX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $10.01B
- Enterprise value
- $7.04B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.0 10-yr median 3.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.23
PCVX key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPCVX valuation Price multiples at each fiscal year-end price.
PCVX returns How much profit the business earns on the capital it uses.
PCVX per-share figures Results divided by the shares outstanding at year-end.
PCVX financial health Debt, liquidity and how easily interest is covered.
PCVX valuation history
PCVX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PCVX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PCVX cash returned to shareholders
PCVX price vs earnings per share
PCVX key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $6.28B | $9.99B | $6.10B | $3.11B | $1.24B | — | — | — | — |
| Enterprise value | $4.95B | $8.31B | $5.05B | $2.20B | $1.01B | — | — | — | — |
| Price / book | 2.3 | 3.0 | 4.9 | 3.3 | 4.3 | — | — | — | — |
| Earnings yield | −12.2% | −4.6% | −6.6% | −7.2% | −8.1% | — | — | — | — |
| Free cash flow yield | −10.7% | −4.8% | −6.0% | −5.7% | −10.4% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Share price at fiscal year-end | $46.14 | $81.86 | $62.80 | $47.95 | $23.79 | $26.57 | — | — | — |
| Per share | |||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | $0.00 | — | — |
| Earnings per share | −$5.63 | −$3.80 | −$4.14 | −$3.44 | −$1.93 | — | −$1.03 | — | — |
| Operating cash flow per share | −$4.82 | −$3.71 | −$3.05 | −$2.63 | −$2.34 | — | −$0.96 | — | — |
| Free cash flow per share | −$4.92 | −$3.89 | −$3.75 | −$2.72 | −$2.46 | — | −$0.99 | — | — |
| Cash per share | $11.47 | $14.32 | $11.12 | $14.36 | $4.74 | — | $1.21 | — | — |
| Book value per share | $19.73 | $27.10 | $12.77 | $14.70 | $5.47 | — | −$2.18 | — | — |
| Tangible book value per share | $19.73 | $27.10 | $12.77 | $14.70 | $5.47 | — | −$2.18 | — | — |
| Capex per share | $0.10 | $0.18 | $0.70 | $0.09 | $0.13 | — | $0.02 | — | — |
| Debt per share | $1.68 | $0.58 | $0.30 | $0.28 | $0.32 | — | $0.01 | — | — |
| Shares outstanding | 136.1M | 122.0M | 97.2M | 64.9M | 51.9M | — | 48.9M | — | — |
| Change in shares outstanding | +11.6% | +25.6% | +49.8% | +25.0% | — | — | — | — | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −25.6% | −20.4% | −36.7% | −36.1% | −31.8% | −74.5% | — | — | −55.7% |
| Return on invested capital (ROIC) | −48.9% | −49.5% | −322.0% | −386.2% | — | — | — | — | — |
| Return on assets (ROA) | −23.4% | −18.9% | −33.3% | −33.6% | −27.9% | −38.9% | −73.7% | −53.4% | −43.5% |
| Return on tangible assets | −25.2% | −13.2% | −28.6% | −22.2% | −30.9% | −22.7% | −76.5% | −41.6% | −43.5% |
| Financial health | |||||||||
| Total debt | $228.8M | $71.1M | $29.2M | $17.9M | $16.8M | — | $611,000 | $3.9M | $4.5M |
| Cash & short-term investments | $1.56B | $1.75B | $1.08B | $931.4M | $246.0M | $386.2M | $59.0M | $66.1M | $36.1M |
| Net debt | −$1.33B | −$1.68B | −$1.05B | −$913.4M | −$229.2M | −$386.2M | −$58.4M | −$62.1M | −$31.6M |
| Debt / equity | 0.09 | 0.02 | 0.02 | 0.02 | 0.06 | — | — | — | 0.15 |
| Debt / assets | 0.08 | 0.02 | 0.02 | 0.02 | 0.05 | — | 0.01 | 0.06 | 0.11 |
| Current ratio | 7.91 | 12.75 | 7.54 | 23.26 | 8.93 | 8.30 | 5.58 | 9.93 | 8.53 |
| Quick ratio | 7.91 | 12.75 | 7.58 | 23.28 | 8.97 | 8.31 | 5.60 | 9.93 | 8.53 |
| Interest coverage | — | — | — | — | — | — | — | -473.8 | — |
| Working capital | $1.42B | $1.65B | $950.6M | $902.0M | $227.6M | $342.1M | $50.7M | $60.0M | $32.1M |
| Invested capital | $1.35B | $1.63B | $189.5M | $40.2M | $54.8M | −$40.4M | −$164.7M | −$119.9M | −$700,000 |
| Tangible asset value | $2.69B | $3.31B | $1.24B | $953.6M | $284.0M | $345.8M | −$106.4M | −$57.7M | $30.9M |
| Net current asset value | $1.27B | $1.58B | $928.5M | $890.0M | $216.0M | $342.0M | −$110.3M | −$61.9M | $27.7M |
| Graham net-net per share | $9.08 | $12.76 | $9.39 | $13.55 | $3.97 | — | −$2.31 | — | — |
| Capital allocation | |||||||||
| Dividends paid | — | — | — | — | — | $374,000 | — | — | — |
| Share buybacks (net) | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / depreciation | 0.55 | 1.42 | 6.67 | 0.62 | 1.90 | 0.82 | 0.97 | 1.71 | 0.00 |
| Efficiency | |||||||||
| Days of inventory on hand | — | — | -17.4 | -43.7 | -152.1 | -64.9 | -59.3 | — | — |
| Days payables outstanding | — | 726.1 | 59.3 | 328.5 | 3,705.1 | 4,307.4 | 919.3 | 816.2 | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Payables turnover | — | 0.50 | 6.15 | 1.11 | 0.10 | 0.08 | 0.40 | 0.45 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $33.6M | $12.1M | $2.3M | $1.1M | $750,000 | $250,000 | $200,000 | — | — |
| Average payables | $59.7M | $31.5M | $12.2M | $8.3M | $18.3M | $16.6M | $3.1M | $2.3M | $1.8M |
| Average inventory | — | — | −$3.6M | −$1.1M | −$750,000 | −$250,000 | −$200,000 | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from PCVX's annual financial statements (latest annual report filed February 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PCVX valuation and financial ratios
Vaxcyte earned a return on equity of −25.6% and a return on invested capital of −48.9% in fiscal 2025. It ended the year with $228.8 million of debt and $1.6 billion in cash and short-term investments, a net cash position of $1.3 billion.
See the PCVX income statement, the PCVX chart for price history, or the PCVX stock overview for the latest quote and news.
PCVX key metrics FAQ
What is Vaxcyte's return on equity?
Vaxcyte's return on equity (ROE) was −25.6% in fiscal 2025: net income of -$766.6 million on average shareholders' equity of $3.0 billion.
What is Vaxcyte's ROIC?
Vaxcyte's return on invested capital was −48.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Vaxcyte have?
Vaxcyte had total debt of $228.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.09 and more cash than debt.
What is Vaxcyte's free cash flow yield?
Vaxcyte generated -$669.3 million of free cash flow in fiscal 2025, a free cash flow yield of −10.7% on its market value at year-end ($6.3 billion).
What is Vaxcyte's current ratio?
Vaxcyte's current ratio was 7.91 at the end of fiscal 2025: current assets were 7.91 times current liabilities.